source
- Teva's anti-IL-15 antibody meets primary endpoint in phase 2a celiac disease trialTeva Pharmaceuticals reported that its anti‑interleukin‑15 antibody, TEV‑408, achieved the primary endpoint in a phase 2a study of 50 adults with celiac disease. Participants received a single dose…
- SEC and FDA sign three-year info-sharing pact to boost market integrity and public-health oversightThe U.S. Securities and Exchange Commission and the Food and Drug Administration have entered into a three-year memorandum of understanding to expand cooperation and share information. The MOU is…